These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000299-15 A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients. 2009-10-06 due-trials
Reported results 2005-003680-22 A double blind, randomised, dose finding, repeat dose, phase II, multicentre study of Alpharadin TM for the treatment of patients with hormone refractory prostate cancer and skeletal metastases. 2009-12-04 due-trials
Reported results 2007-006195-11 A double blind, randomised, multiple dose, phase III, multicentre study of AlpharadinTM in the treatment of patients with hormone-refractory prostate cancer with skeletal metastases 2014-02-13 due-trials
Reported results 2009-012189-30 An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy 2012-02-16 due-trials